February 21, 2014
The Fifth Circuit on Friday upheld victories for brand-name and generic makers of the heartburn drug Reglan in two personal injury lawsuits, rejecting the plaintiffs' assertion that their claims against the generic makers are not preempted because they parallel federal law.